Genostim Performance Labs
Strategic Sales Initiative — Version 3
Three-Stream Revenue Architecture · Human Peptides · Pet Peptides · Collagen B2B
Prepared by TIN | Pet Jet LLC | Scale Foundry | Velocity Partners · April 2026 · CONFIDENTIAL
At a Glance
The Initiative in Three Streams
3
Revenue Streams
Human Peptides · Pet Peptides · Collagen B2B — operating in parallel
$83M
Year-5 Revenue Target
Combined base case across all three streams
20%
Equity Stake Offered
15–20% aggregate; 3-yr vest / 1-yr cliff; no cash fees
M16
Cash Breakeven
Projected Month 16–18 combined across all streams
Chapter 1
Executive Summary
Version 3 of the Strategic Sales Initiative introduces a fully architected, three-stream revenue model designed to translate 20 years of proprietary peptide science and collagen R&D into a scalable, multi-vertical business. Three completely separate revenue streams — each with its own brand, regulatory framework, commercial team, and go-to-market strategy — operating in parallel from Day 1.
The Science Edge
The Isotide™/Hexatide™ Complex — 18 amino acids, 21 growth factors, pinocytosis delivery — supports ten documented benefit pillars across human and companion animal applications.
The Proposal
Pet Jet LLC Advisory Consortium offers a 15–20% equity stake in exchange for full sales infrastructure, channel development, technology, and financial advisory. No fees. Equity only.
Executive Summary
Three Streams. One Science Platform.
Stream 1 — Human Peptides
Genostim® Collagen Science · TAM: $2.5B | SAM: $900M · Y1: $0.9M → Y5: $22.5M · Regulatory: DSHEA · Lead: TIN
Stream 2 — Pet Peptides
The Gift For Life® (TGFL®) · TAM: $4.76B | SAM: $1.7B · Y1: $1.0M → Y5: $20M · Regulatory: AAFCO/NASC · Lead: Pet Jet LLC
Stream 3 — Collagen B2B (NEW)
Ingredient supply to F&B, Nutra, Cosmetics, Pharma · TAM: $2.7B | Ambition: 1.5% · Y1: $0.2M → Y5: $40.5M · Lead: TIN + Velocity Partners
Combined Base Case: $2.1M (Y1) → $83M (Y5) | Stretch: $38M (Y3) / $110M+ (Y5)
Chapter 2 · Market Dynamics
Three Markets. One Proprietary Science Platform.
The timing for all three streams is favorable simultaneously: the human functional supplement market is bifurcating toward clinical-grade products; the pet supplement market is experiencing its fastest growth decade; and domestic collagen ingredient sourcing has become a strategic priority for US brands post-COVID. Genostim's 20-year R&D investment serves all three markets without additional fundamental science investment.
Market Dynamics
Combined Revenue & Investment Summary
Each stream builds independent brand equity, customer relationships, and recurring revenue that compound separately and can ultimately be separated, licensed, or sold independently.
Market Dynamics
Why Three Streams — Why Now
The Strategic Logic
Genostim's 20-year R&D investment in peptide science and bovine collagen technology creates a unique asset base that can serve multiple markets simultaneously without additional fundamental science investment. The differentiation across streams is in application, formulation, regulatory positioning, and channel strategy — not in the core science.
Risk Management + Value Creation
This separation is both a risk management strategy and a value creation strategy. A regulatory setback in one stream does not contaminate the others. Each stream builds independent brand equity, customer relationships, and recurring revenue.
Human Market
Bifurcating toward clinical-grade products post-pandemic — white space for 'Clean. Clinical. Powerful.'
Pet Market
Fastest growth decade driven by pet humanization and millennial pet ownership
B2B Collagen
Domestic sourcing is a strategic priority post-COVID — Made-in-USA commands a premium
Chapter 3 · Revenue Forecast
5-Year Three-Stream Revenue Build
Combined base case: $2.1M (Y1) → $83M (Y5). B2B becomes the largest stream by revenue in Year 4.
Revenue Forecast
Stream Targets at a Glance
Cash breakeven: Month 16–18 combined. Human + pet streams may break even by Month 14 independently.
Chapter 4 · Quarterly Forecast
Human Stream — Quarterly Revenue Ramp
Total revenue ramps from $75K in Q1Y1 to ~$2.7M in Q4Y3, with DTC/Amazon leading early growth and HCP, affiliate, and retail channels scaling in sequence.
Q1–Q2 revenue is DTC/Amazon dominated. HCP channel begins contributing in Q3. Affiliate reaches meaningful scale by Q4. Retail contribution begins Q2-Y2.
Quarterly Forecast · Key Inflection Points
When Each Stream Reaches Critical Mass
1
Month 3
All three streams activated simultaneously. Genostim® + TGFL® Shopify live. Amazon FBA live. TGFL® Chewy listing active. Clinical study enrollment begins.
2
Month 6
B2B processing partner LOI signed. GMP certification gap assessment complete. 50 HCP clinics onboarded. Chewy autoship promotions active.
3
Month 9
Retail buyer meetings begin (Natural Grocers, Vitamin Shoppe). 100 active affiliates generating $50K+ GMV. 150 vet clinic accounts active.
4
Month 12
Full RCT commissioned ($250–500K). Specialty retail regional tests begin. B2B first anchor contracts signed. Human + pet streams approaching breakeven.
5
Month 16–18
Combined cash breakeven across all three streams. B2B begins meaningful revenue contribution. National retail rollout discussions.
Chapter 5 · Channel Playbooks
Three Streams. Eleven Channels. One Revenue Engine.
Each stream operates with complete independence — separate brand, regulatory framework, commercial team, and channel strategy. The same underlying collagen peptide science powers all three.
Stream 1 · Channel 1.1
DTC / Amazon — Primary Acquisition Engine
Genostim® Collagen Science | Lead: TIN | Regulatory: DSHEA
The DTC and Amazon engine is the core direct-response growth channel for Stream 1 — combining clinical credibility, marketplace scale, and efficient paid acquisition.
Shopify Storefront
Rebuilt with clinical credibility UX. Hero: 20-year R&D story. Target: 3.5% DTC conversion rate.
Amazon FBA
5 priority SKUs — Genostim® Collagen Peptides, GHK-Cu Serum Support, ISOTIDE™ Recovery Formula, Skin + Joint Bundle, Clinical Collagen Powder.
Subscribe & Save
45% autoship enrollment target by Month 12 (vs. 30–35% industry avg). 15% autoship discount.
Pricing & Media
Retail pricing: $65–$85/unit. Subscribe & Save: $55–$72. HCP wholesale: $32–$38. Paid media: Meta + YouTube, $15K/month initial → $40K/month by Month 9.
Stream 1 · Channel 1.2
Health Professional (HCP) Channel
Patients referred by practitioners have 2–3x the LTV of DTC customers, require no paid acquisition cost, and provide the social proof loop.
Practitioner Targets
Functional medicine MDs/DOs, sports medicine physicians, chiropractors, naturopathic doctors (NDs), registered dietitians, integrative health coaches.
Medical Educator Role
Month 2 hire. Clinically credentialed professional — not a traditional sales rep. Compensation: base + equity.
50-Clinic Initial Cohort
Selected by (1) existing collagen/peptide prescribing behavior, (2) patient panel >500, (3) geographic concentration.
CE Education Program
1-hour CE session on collagen peptide science, GHK-Cu mechanisms, ISOTIDE™ characterization.
HCP Revenue Economics
Wholesale 40–45% of retail. Target: 150 active HCP accounts by Month 12, each ordering 2 cases/month = $500K+ annualized HCP revenue.
Stream 1 · Channel 1.3
Affiliate & Influencer Program
The 20% recurring commission — not one-time — is the key differentiator that attracts high-quality affiliates in the biohacking and longevity space.
  • Platform: ShareASale (primary) + Impact Radius (secondary). 90-day cookie window.
  • Commission Architecture: 20% recurring for 12 months → 15% lifetime recurring. Top-tier (>$5K/month GMV): 22% + quarterly bonus.
  • Biohacking Community: Ben Greenfield, Huberman Lab, Dave Asprey/Bulletproof adjacent creators.
  • Longevity & Skin Health: Dermatology-adjacent influencers, anti-aging content creators, 'science-based beauty' audience.
  • Sports Performance: Athletic recovery, CrossFit community. ISOTIDE™ recovery positioning.
  • Influencer Tier Strategy: Tier 1 Micro (10K–100K): 80% of budget in Y1. Tier 2 Mid (100K–1M): Month 6+. Tier 3 Macro (1M+): Year 2 with clinical data.
Stream 1 · Channel 1.4
Specialty Retail — Phase 2 (Month 12–18)
Retail Strategy
Specialty retail is deliberately Phase 2. Retail buyers require sales velocity data, clinical credibility, and brand awareness before committing shelf space. DTC and Amazon performance in Months 1–12 builds the data package retail buyers need.
Retail Partners
  • Vitamin Shoppe: ~720 US locations. 250-store regional test target Month 15.
  • Natural Grocers: ~165 locations in 20 states. Strictest ingredient standards. 50-store West Coast test Month 14.
  • GNC: ~2,400 US locations. Reserved for Phase 3 (Month 18+).
Retail Infrastructure
  • UNFI and KeHE broker relationships via consortium network. Broker commission: 5–8% of net selling price.
  • EDI compliance and retailer portals configured Month 10–11.
Retail Buyer Package
SPINS category data, Amazon velocity screenshots, clinical pilot summary, brand sell sheet, and planogram recommendations.
Stream 2 · Channel 2.1
Veterinary Clinics — Highest-LTV Pet Channel
Vet-recommended products are purchased with prescription-level compliance, have near-zero price sensitivity, and generate deep autoship loyalty.
  • Primary Distributors: MWI Animal Health (largest US vet distributor), Patterson Veterinary (2nd largest), Covetrus (formerly Henry Schein Animal Health). Pet Jet LLC has existing relationships with regional reps at all three.
  • CE Education Program: 1-hour presentation for DVMs and vet techs covering collagen peptide mechanisms, Peptide Effect series data, GHK-Cu in wound healing/skin. CE credits via AAVSB RACE program.
  • Clinic Protocol Integration: DVM recommends TGFL® at discharge for joint health, post-surgery recovery, senior wellness, coat/skin conditions. Discharge recommendation = high autoship conversion.
  • Clinic Economics: Vet wholesale: 35–40% of MSRP. Consignment option for first order. Year 1 Target: 150 vet clinic accounts active.
  • Geographic Focus: Texas (DVM relationship base), California, Florida (senior pet demographics), New York/New Jersey.
Stream 2 · Channel 2.2
DTC / Chewy — The Autoship Engine
Chewy.com has $11B+ in annual net sales with 82% of sales through autoship — the highest autoship penetration of any major e-commerce platform.
  • Chewy Autoship Priority: Target 65% of Chewy buyers enrolled in autoship within 90 days of first purchase. Chewy's 10–15% autoship discount funded by Genostim.
  • Soft Chew Format: Soft chews hold 35% of the pet supplement market by format. TGFL® launches in soft chew first; powder option added Month 6.
  • thegiftforlife.com: Shopify build — completely independent from Genostim® human storefront in branding, copy, and creative. DTC site is the brand home; Chewy is the volume channel.
  • DTC-First Strategy: Months 1–3 DTC-only to capture brand margin and build email list. Chewy listing goes live Month 4.
  • Amazon Pet: Dedicated TGFL® brand store — separate from human Genostim® Amazon presence. A+ content emphasizing vet endorsement and soft chew palatability.
Stream 2 · Channel 2.3
Pet Specialty Retail — Mass Distribution
PetSmart and Petco combined have ~3,200 US locations; Pet Supplies Plus adds ~650. Physical shelf presence signals brand legitimacy and drives search/DTC traffic.
  • PetSmart: ~1,700 US locations. TGFL® enters at premium/clinical tier with vet endorsement differentiator vs. 'Whole Hearted' private label.
  • Petco: ~1,500 US locations. 'Whole Health' positioning aligns with TGFL®'s science-forward branding. More aggressive in adding clinical-credential supplement brands.
  • Pet Supplies Plus: ~650 franchise locations. Midwest/Southeast concentration. Faster buyer decision cycle — useful for initial test.
  • Entry Strategy: 50-store Petco regional test (West Coast, Month 12) using Pet Jet LLC's existing Petco buyer relationship. National pitch Month 18.
  • Category Positioning: TGFL® competes in joint health + mobility and coat/skin — two of the fastest-growing pet supplement segments.
Stream 3 · NEW
Collagen Ingredient B2B — A Distinct Business Model
The Opportunity
Rather than selling finished products to consumers, Genostim becomes an ingredient supplier — selling premium collagen at $20–45/kg on 12–24 month contracts to food & beverage manufacturers, nutraceutical brands, cosmetic formulators, and pharmaceutical companies. Starting from 0% market penetration. Targeting 1.5% of the $2.7B global collagen ingredient TAM by Year 5 = $40.5M.
B2B Revenue Ramp
Why Genostim Wins in B2B
  • Made in USA (Texas) — domestic sourcing preference accelerating post-COVID
  • Grass-fed bovine — recognized premium claim with consumer willingness-to-pay
  • 20 years of proprietary peptide R&D — Rousselot and Gelita are manufacturers; Genostim is a research company
  • Characterized bioactive fractions (GHK-Cu, ISOTIDE™) — impossible with commodity suppliers
  • Clinical co-branding ability — B2B clients can co-brand clinical data in their own marketing
Stream 3 · Collagen B2B
Four B2B Channels — From Food to Pharma
Channel 3.1 — Food & Beverage
Longest sales cycle (6–18 months), largest contracts ($2–5M/yr). Target: protein bar brands, functional beverages, yogurt producers, bone broth manufacturers. Trade shows: SupplySide West, IFT FIRST.
Channel 3.2 — Nutraceutical / Private Label
Fastest-close B2B segment (3–6 months). Mid-size supplement brands ($10M–$500M revenue) sourcing collagen ingredient. White label option generates higher per-unit margin.
Channel 3.3 — Cosmetics Formulators
Sales cycle 3–9 months. GHK-Cu copper peptide has strong organic cosmetics community interest. Cosmetics-grade collagen at $34–42/kg; GHK-Cu fraction at $40–50/kg.
Channel 3.4 — Pharmaceutical & Medical (Year 3+)
Longest cycle (18–36 months), highest margin (45–60%). Wound care matrices, hemostatic agents, injectable fillers, drug delivery systems. Requires GMP certification and Drug Master File (DMF).
Lead: TIN (strategic relationships) + Velocity Partners (international channels, Year 3+)
Chapter 7 · Financial Model
36-Month Financial Model — All Three Streams
$2.1M
Year 1 Combined Revenue
Human $0.9M + Pet $1.0M + B2B $0.2M
$500K
Initial Co-Investment
Covers regulatory counsel, Shopify rebuild, clinical study SOW, B2B sales hire, 3 months runway
$90K
Monthly Fixed OpEx
Consortium team allocation, shared infrastructure, minimum staffing for all 3 streams
M16–18
Combined Cash Breakeven
Human + pet may break even by M14; B2B delays combined breakeven by 2–4 months
The 36-month base case projects cumulative revenue of approximately $53M over three years, reflecting compounding subscriber accumulation, channel diversification, and organic traffic growth.
Consumer streams (human + pet) generate positive unit economics within 6 months. The B2B collagen stream has a longer ramp but contributes disproportionately to margin in Years 3–5.
36-Month Financial Model
Unit Economics & Cost Structure
Margin & COGS
55% Gross Margin — Human/Pet
DTC: 65–70%; HCP wholesale: 40–45%; Specialty retail: 35–40%. Subscribe & Save autoship reduces LTV-adjusted CAC substantially.
35–45% Gross Margin — Collagen B2B
Pharmaceutical-grade: 45%+. Commodity food-grade: 30–35%. Characterized ISOTIDE™ fraction commands premium above all.
Marketing Spend
Year 1: 35% of consumer revenue. Year 2: 25%. Year 3: 18%. B2B marketing cost is trade show + sales salaries (separate line).
Capital Deployment — 90-Day Buckets
Bucket 1 — Regulatory & Science ($120K)
FDA regulatory counsel retainer, clinical study SOW, ISOTIDE™ NDI analysis.
Bucket 2 — Digital Infrastructure ($140K)
Shopify rebuild for Genostim® + TGFL®, CRM/email (Klaviyo), Amazon Brand Registry, affiliate platform.
Bucket 3 — B2B Launch & Team ($120K)
B2B sales hire, trade show registrations (SupplySide West, IFT FIRST), processing partner evaluation.
Operating Reserve ($120K)
4 months of $90K/month fixed OpEx partially covered. Bridges to Month 8–10 without additional capital.
36-Month Financial Model
Investment & Exit Potential
$500,000
Initial consortium co-investment at closing — co-investment earns equity-equivalent return, treated as founder-round capital
$83M
Year 5 base case revenue — Human $22.5M + Pet $20M + B2B $40.5M
$250–330M
Implied enterprise value at Year 5 — 3–4x revenue multiple at 55% blended gross margin
Strategic Exit
Supplement conglomerate or food ingredient company most likely acquirer — each stream can be separated, licensed, or sold independently
Chapter 8 · Consortium Engagement Model
Advisory for Equity — Integrated Execution Team
The consortium model is fundamentally different from traditional advisory arrangements. Each consortium partner has a defined lane with specific, measurable deliverables, dedicated team allocation to Genostim, and compensation tied entirely to long-term equity value creation. There are no hourly fees, no monthly retainers, and no per-project charges. The $500K co-investment signals genuine skin-in-the-game — consortium partners are putting capital at risk alongside Genostim, not just time.
TIN
Lead: Human HCP channel, B2B collagen ingredient relationships, financial advisory, market intelligence
Pet Jet LLC
Lead: All pet channel activities (Stream 2)
Scale Foundry
Lead: AI marketing infrastructure, content engine, paid media
Velocity Partners
Lead: International distribution (Year 3+), financial structuring, international B2B ingredient distribution
Advisory for Equity
Why Equity Over Commission?
Commission Model
Incentivizes transaction volume but not business quality. Optimizes for next month's sales number — not long-term brand value or stream architecture. Creates misalignment when difficult decisions must be made.
Equity Model
Every consortium partner earns exclusively through equity appreciation — creating complete alignment with Genostim's long-term value creation. The 3-year vest with 1-year cliff ensures partners are committed for the full execution period and cannot extract equity without delivering results.
The consortium brings distribution relationships, AI marketing infrastructure, financial advisory, regulatory guidance, and clinical development management that would individually cost $2–5M to acquire on the open market.
Advisory for Equity
Engagement Terms
Advisory for Equity
Equity Value Creation Path
At $83M revenue and 55% blended gross margin, a 3–4x revenue multiple implies a $250–330M enterprise value in Year 5. 15% stake = $37.5–49.5M. 20% stake = $50–66M.
Chapter 9 · Sales Operations
Sales Operations Infrastructure — Three Streams
Executing the three-stream strategy requires purpose-built infrastructure — CRM, order management, analytics, and fulfillment systems that serve all three streams simultaneously while maintaining complete brand separation between human and pet channels. The B2B stream requires dedicated enterprise sales infrastructure distinct from consumer channels.
Digital Infrastructure
  • Shopify (Genostim® + TGFL® — separate builds)
  • Amazon Brand Registry (separate accounts)
  • Klaviyo CRM/email
  • Affiliate platform (ShareASale + Impact Radius)
B2B Infrastructure
  • Processing partnership (Texas-based, Month 1–6)
  • GMP certification (Month 6–12)
  • COA & specification documentation
  • Trade show presence (SupplySide West, IFT FIRST, Expo West)
Analytics & Reporting
  • Monthly ROAS reporting (Scale Foundry)
  • Quarterly board-level reporting
  • Stream-level P&L tracking
  • KPI dashboard per stream
Sales Operations Infrastructure
Key Performance Indicators — By Stream
Chapter 9 · Competitive Landscape
Competitive Landscape & Market Context
Each stream faces different competitors, different competitive dynamics, and different defensibility strategies. The three-stream architecture is itself a primary competitive advantage — no single competitor operates across all three markets with the same underlying science platform.
Stream 1: Human Market
$2.5B TAM growing 7–9% annually. Bifurcating toward clinical-grade. Genostim® white space: Clinical peptide specialization + 20-yr R&D + HCP channel + biohacking community + Made-in-USA. No single competitor combines all five.
Stream 2: Pet Market
$4.76B TAM growing 8–10% annually. Driven by pet humanization, aging pet population, and e-commerce subscription penetration. TGFL® targets the premium/clinical tier above Zesty Paws with peptide science differentiation.
Stream 3: B2B Collagen
$2.7B global TAM. Two-player oligopoly (Rousselot + Gelita) — both European-sourced commodity suppliers. The premium ingredient tier with clinical documentation, domestic sourcing, and brand co-marketing ability is essentially unoccupied.
Risk Management
Key Risks & Mitigation Strategies
The three-stream architecture is itself a primary risk mitigation — a setback in one stream does not impair the other two.
Chapter 10 · Next Steps
Immediate Next Steps — 90-Day Sprint
Execution begins immediately upon term sheet execution. The 90-day sprint is designed to activate all three streams simultaneously rather than sequentially. The goal: by Day 90, all three streams have committed infrastructure, initial customer contacts, and a clear 12-month execution path.
01
Phase 1 (Week 1–2)
Structure & Commitment — Execute advisory-for-equity term sheet. Establish consortium operating entity. Deploy $500K co-investment. Kick-off call with all consortium partners + Genostim leadership.
02
Phase 2 (Week 2–6)
Foundation Activation — FDA counsel engaged. Shopify rebuild begins. B2B processing partner evaluation. Pet Jet LLC activates MWI and Patterson distributor conversations. Clinical study RFP sent.
03
Phase 3 (Month 2–3)
Launch Preparation — Clinical study SOW executed. DTC Marketing Lead + Medical Educator hired. Affiliate program live on ShareASale. HCP target list of 50 clinics finalized. TGFL® Chewy listing approved.
Engagement Terms
Five Steps to Kickoff
01
Mutual NDA Execution
Pet Jet LLC ↔ Genostim Performance Labs — executed at first meeting
02
Data Room Preparation
Genostim prepares financials, customer data, COGS detail, and IP inventory
03
Consortium Due Diligence
2-week confidential process conducted by the consortium
04
Term Sheet Delivery & Negotiation
Equity terms, vesting schedule, and services scope finalized
05
LOI Execution → Phase 1 Kickoff
Letter of Intent signed; engagement commences; Phase 1 infrastructure build begins
The Consortium
Who Is Behind This Initiative?
TIN
Lead: Human HCP channel, B2B collagen ingredient relationships, financial advisory, market intelligence. Deliverables: 50 HCP clinic outreach by Month 3, first B2B prospect meeting by Month 2, 36-month financial model maintained.
Pet Jet LLC
Lead: All pet channel activities (Stream 2). Deliverables: MWI and Patterson vet distributor meetings by Month 2, TGFL® Chewy listing live by Month 4, 50 vet clinic accounts active by Month 9.
Scale Foundry
Lead: AI marketing infrastructure, content engine, paid media. Deliverables: Content engine live (3 articles/week) by Month 3, Shopify rebuild complete by Month 3, paid social ROAS reporting monthly.
Velocity Partners
Lead: International distribution (Year 3+), financial structuring support, international B2B ingredient distribution. Deliverables: International market analysis by Month 6, ingredient broker introductions by Month 4.
Summary
Why This Initiative Wins
Differentiated Science
20 years of proprietary peptide R&D. Characterized bioactive fractions (GHK-Cu, ISOTIDE™) that commodity suppliers cannot replicate.
Three-Stream Risk Architecture
A regulatory setback in one stream does not contaminate the others. Each stream builds independent brand equity and recurring revenue.
$83M Year-5 Base Case
Human $22.5M + Pet $20M + B2B $40.5M. B2B becomes the largest stream by revenue in Year 4.
Aligned Consortium
TIN | Pet Jet LLC | Scale Foundry | Velocity Partners — all earning exclusively through equity appreciation. $500K co-investment creates Day 1 alignment.
$250–330M Exit Potential
At $83M revenue and 55% blended gross margin, a 3–4x revenue multiple implies a $250–330M enterprise value in Year 5.
Ready to Build Something Exceptional
Version 3 of the Strategic Sales Initiative represents Genostim Performance Labs' most ambitious commercial phase — a fully architected, three-stream revenue model built on 20 years of proprietary peptide science. The consortium is prepared to execute a term sheet and begin work upon agreement on equity terms.
Contact
joey@mypetjet.com · mypetjet.com
Date
April 2026
Classification
CLIENT PROPOSAL — CONFIDENTIAL · Not for distribution
$83M
Combined Base Case
Y1 to Y5 from $2.1M
$110M+
Stretch Scenario
Year 5
15–20%
Equity Stake
Offered to consortium
$500K
Co-Investment
At closing